Intensity Therapeutics (INTS) Q2 2026 earnings review
Clinical Trials Restart on ATM Funding, But Cash Constraints Persist
Intensity Therapeutics is a pre-revenue biotech where the story revolves entirely around clinical data and capital preservation. The company successfully reversed its 2025 trial pauses, restarting patient treatment in both the Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 studies. Preliminary TNBC data from INVINCIBLE-4 is highly encouraging, showing a massive efficacy advantage over the standard of care. However, survival comes at a steep cost to shareholders: the company continues to rely on its $60M ATM facility, driving massive dilution. With only $9.5M in cash against a quarterly burn rate that is accelerating back to $3.0M, funding remains an existential overhang.
🐂 Bull Case
Early data from the INVINCIBLE-4 study showed a 71% pathological complete response (pCR) rate for INT230-6 combined with standard-of-care, vastly outperforming the 42% pCR in the control arm.
Following severe funding constraints in early 2025, the company has officially resumed operations in both of its critical late-stage clinical trials across the US and Europe.
🐻 Bear Case
Weighted average shares outstanding exploded from 0.75 million in Q2 2025 to 2.7 million in Q2 2026 as the company taps its At-The-Market (ATM) facility just to keep the lights on.
With $9.5M in cash at quarter-end and R&D expenses ramping back up, the company lacks the independent capital required to see its Phase 3 trial through to completion without securing a partner or raising highly dilutive equity.
⚖️ Verdict: ⚪
Neutral. The clinical data for INT230-6 is exceptionally promising and derisks the science, but the microscopic cash position and heavy reliance on ATM dilution make this uninvestable for those sensitive to capital structures.
Key Themes
INVINCIBLE-4 Shows Remarkable Early Efficacy and Safety
Preliminary data from the first 14 patients in the Phase 2 INVINCIBLE-4 TNBC study is a massive win for the DfuseRx platform. The INT230-6 treatment arm (Cohort A) demonstrated an accelerating 71% pathological complete response (pCR) compared to just 42% for the standard-of-care (Cohort B). More impressively, Cohort A saw a 44% reduction in grade 3 adverse events. This dual benefit of higher efficacy and lower toxicity is a textbook driver for eventual regulatory success and potential partnership interest.
Reversing the 2025 Clinical Pause
Management has officially transitioned from "survival mode" back to "execution mode." The devastating clinical trial pauses from March and September 2025—which halted site activations due to funding and a dosing regimen review—are now reversing. Patient treatment restarted in INVINCIBLE-4 in July 2026 (including a new site in France), and limited US enrollment for the Phase 3 INVINCIBLE-3 trial is queued for Q3 2026.
The Brutal Reality of ATM-Driven Dilution
While the clinical narrative is accelerating, the financial structure is deteriorating. The company utilized $1.6M net from its $60M ATM in Q2, plus another $1.3M post-quarter. Consequently, outstanding share counts have nearly quadrupled YoY. If Intensity cannot secure a non-dilutive strategic partnership soon, retail investors will continue to bear the brunt of trial financing.
Cash Position Contradicts Aggressive Clinical Timeline
Despite management's optimism regarding trial expansion, the balance sheet tells a cautious story. Cash reserves decelerated from $11.9M at the end of 2025 to $9.5M in Q2 2026. The company explicitly states that "enrollment rates are expected to increase as sufficient funding is obtained," clearly admitting that their current balance sheet cannot support full Phase 3 execution without further capital injections.
Other KPIs
Accelerating. R&D increased 19% YoY from $1.54M in Q2 2025. Sequentially, it jumped from $1.19M in Q1 2026. This reflects the direct cost of re-initiating the INVINCIBLE-3 study in April and preparing the European sites for INVINCIBLE-4.
Stable. Up slightly from $1.16M YoY, driven by an estimated bonus accrual and higher franchise costs, though partially offset by zero stock-based compensation grants in the first half of 2026.
Decelerating cash preservation. The company posted a $3.08M operating loss. Moving forward, as enrollment sites activate across France, Switzerland, and the US, this burn rate is highly likely to accelerate in H2 2026.
Guidance
Reversing a prior pause. Management guided that patient enrollment will resume in a limited capacity in Q3 2026 using an FDA-reviewed amended protocol. Full-scale site activation is explicitly gated by the acquisition of additional funding.
Stable target, but extends the timeline. Following the protocol amendment in Switzerland and France to adjust the dosing regimen, management targets complete enrollment for this 54-patient Phase 2 trial by late 2027.
Key Questions
Partnership Timelines vs ATM Reliance
Management mentioned holding meetings with strategic partners at the BIO International Conference in June. Given the $9.5M cash balance, what is the realistic timeline for securing a partnership before needing to lean more aggressively on the $60M ATM?
Scaling INVINCIBLE-3
You noted that INVINCIBLE-3 enrollment will resume at a 'limited number of U.S. sites.' What specific dollar amount of new funding is required to transition this from a limited restart to full global enrollment?
INVINCIBLE-4 Cohort A Durability
The 71% pCR rate for INT230-6 in early-stage TNBC is highly compelling. Have you observed any early trends in durability or disease-free survival for these initial 7 patients post-surgery?